A $435 Million Bet on 'Reversing Aging'

A $435 Million Bet on ‘Reversing Aging’

June 6, 2026

Biotech startup NewLimit secures a major funding round after claiming a ‘breakthrough discovery’ of a prototype medicine that rewinds cellular aging in the liver.

Search

RECENT PRESS RELEASES

Investors seek protection as South Korea’s stock rally shows signs of overheating

SWI Editorial Staff2026-06-06T19:41:55-07:00June 6, 2026|

Earnings Miss and Pipeline Expansion Might Change The Case For Investing In MPLX (MPLX)

SWI Editorial Staff2026-06-06T19:22:14-07:00June 6, 2026|

A $435 Million Bet on ‘Reversing Aging’

SWI Editorial Staff2026-06-06T19:20:08-07:00June 6, 2026|

Strong Q3 Beat And Upbeat Outlook Might Change The Case For Investing In H&R Block (HRB)

SWI Editorial Staff2026-06-06T19:12:06-07:00June 6, 2026|

Don’t Wait: Right Now Is an Excellent Opportunity to Rebalance Your Portfolio

SWI Editorial Staff2026-06-06T18:50:00-07:00June 6, 2026|

The Weekly Notable Startup Funding Report: 6/8/26

SWI Editorial Staff2026-06-06T18:27:17-07:00June 6, 2026|